Furthermore, we have previously shown that combinatorial inhibition of SHP2 with other MAPK or PI3K components results in synergistic growth inhibition of neuroblastoma and other pediatric malignancies bearing RAS- or PI3K-activating mutations (30, 59). Here, PTPN11 is linked to neuroblastoma.